Acne Cure News

Dapsone Archives

Activity of Dapsone versus Community and Hospital Pathogens from the CANWARD Study

Topical dapsone gel is a sulfone antibiotic approved for acne treatment. No microbiology studies were conducted during dapsone gel clinical trials and it is unclear whether 1) dapsone has antimicrobial activity that may be of clinical relevance in dermatology and 2) dapsone could affect the normal microbiome of facial skin where it is most commonly applied. This study assessed the in vitro activity of dapsone versus Gram-positive and Gram-negative bacterial pathogens obtained from patients with infections.

What’s new in acne and rosacea?

Acne and rosacea are common conditions seen every day by dermatologists. This review will discuss the most recent therapeutic options for patients with these conditions. Specifically, for acne, there will be a discussion of the use of isotretinoin at higher cumulative doses as well as a new formulation of isotretinoin, isotretinoin-lidose.

The use of oral antibiotics in treating acne vulgaris: a new approach

Although acne is not an infectious disease, oral antibiotics have remained a mainstay of treatment over the last 40 years. The anti-inflammatory properties of oral antibiotics, particularly the tetracyclines, are efficacious in treating inflammatory acne lesions. Common prescribing practices in Dermatology exert significant selection pressure on bacteria, contributing to the development of antibiotic resistance.

Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials

The objective of this study was to assess the efficacy and safety of a new, once-daily formulation of dapsone gel, 7.5%, with a 50% higher dapsone concentration, versus vehicle over 12 weeks in patients with acne.

Once-daily topical dapsone gel 7.5% for acne vulgaris: Pooled efficacy and safety data from two pivotal studies

New, once-daily dapsone gel 7.5% (DAP) was developed to simplify topical antiinflammatory acne treatment relative to twice-daily Aczone® Gel 5%. Pooled data from 2 identically designed, randomized, double-blind, vehicle (VEH)-controlled pivotal studies of DAP for acne assessed overall safety and efficacy of once-daily DAP treatment.

Five recent developments in acne.

The FDA’s approval of Allergan plc’s Aczone Gel, 7.5% as a once-daily topical treatment for patients with acne was a recent development reported on Other recent developments included research presented at the American Academy of Dermatology Annual Meeting on acne treatment and the public’s misconceptions of patients with acne.